HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 182 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $547,096 | -6.8% | 16,690 | +0.0% | 0.00% | – |
| Q2 2023 | $587,097 | -65.0% | 16,686 | -67.5% | 0.00% | -100.0% |
| Q1 2023 | $1,677,564 | -97.6% | 51,377 | -96.0% | 0.00% | -98.0% |
| Q4 2022 | $71,194,299 | +6.0% | 1,292,135 | -57.4% | 0.05% | +2.0% |
| Q3 2022 | $67,175,108 | -3.3% | 3,030,206 | +112.6% | 0.05% | +4.2% |
| Q2 2022 | $69,501,000 | -11.0% | 1,425,168 | -11.2% | 0.05% | +26.3% |
| Q1 2022 | $78,075,000 | +18.6% | 1,604,909 | +4.0% | 0.04% | +40.7% |
| Q4 2021 | $65,827,000 | +40.8% | 1,543,724 | +26.6% | 0.03% | +35.0% |
| Q3 2021 | $46,746,000 | +31.3% | 1,219,559 | -3.3% | 0.02% | +33.3% |
| Q2 2021 | $35,610,000 | -6.6% | 1,261,392 | +9.3% | 0.02% | -11.8% |
| Q1 2021 | $38,120,000 | -3.6% | 1,153,783 | +5.4% | 0.02% | -5.6% |
| Q4 2020 | $39,562,000 | +33.4% | 1,094,449 | +25.1% | 0.02% | +20.0% |
| Q3 2020 | $29,661,000 | – | 874,909 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $618,113,619 | 97.50% |
| venBio Partners LLC | 1,035,396 | $57,050,320 | 17.69% |
| Vivo Capital, LLC | 2,606,247 | $143,604 | 16.53% |
| Nan Fung Group Holdings Ltd | 368,665 | $20,313,442 | 14.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 264,500 | $14,560,725 | 4.50% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 685,340 | $37,762,234 | 3.51% |
| ASHFORD CAPITAL MANAGEMENT INC | 356,638 | $19,650,754 | 3.05% |
| TANG CAPITAL MANAGEMENT LLC | 281,200 | $15,494,120 | 2.25% |
| MPM BioImpact LLC | 139,377 | $7,679,673 | 1.99% |
| O'Neil Global Advisors, Inc. | 7,335 | $404 | 1.86% |